Adjuvant endocrine therapy with cyclin-dependent kinase 4/6 inhibitor, ribociclib, for localized hormone receptor-positive/HER2- breast cancer (LEADER)
使用细胞周期蛋白依赖性激酶 4/6 抑制剂 ribociclib 进行辅助内分泌治疗，用于治疗局部激素受体阳性/HER2- 乳腺癌（LEADER）
期刊:NPJ Breast Cancer
影响因子:7.6
doi:10.1038/s41523-024-00708-5
Spring, Laura M; Scarpetti, Lauren; Medford, Arielle J; Niemierko, Andrzej; Comander, Amy; Mulvey, Therese; Schnipper, Lowell; Isakoff, Steven J; Moy, Beverly; Wander, Seth A; Shin, Jennifer; Ephrem, Zanta; Laposta, Anneke R; Denault, Elyssa; Abraham, Elizabeth; Calistro, Gayle; Kalashnikova, Ekaterina; Rodriguez, Angel; Liu, Minetta C; Aleshin, Alexey; Peppercorn, Jeffrey; Ellisen, Leif W; Bardia, Aditya
肿瘤
HER2
肿瘤免疫
信号转导
乳腺癌
细胞生物学
免疫/内分泌
